Neurocrine Biosciences | NBIX - Ebitda


Neurocrine Biosciences reported $218.4M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
AbbVie USD 3.52B 828M Sep/2025
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
Agios Pharmaceuticals USD -115.49M 10.3M Sep/2025
ALKERMES USD 121.55M 4.99M Sep/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
Biogen USD 573.2M 253.7M Dec/2025
BioMarin Pharmaceutical USD -5.26M 300.71M Sep/2025
Cytokinetics USD -277.18M 169.36M Sep/2025
Exelixis USD 248.93M 28.02M Sep/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Halozyme Therapeutics USD 21.9M 226.34M Dec/2025
Incyte USD 414.5M 92.42M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Pfizer USD 6.08B 351M Sep/2025
Prothena USD -39.53M 12.25M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Repligen USD 39.54M 3.61M Dec/2025
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Teva Pharmaceutical Industries USD 1.64B 243M Dec/2025
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025
Xoma USD 2.52M 7.98M Jun/2024